Research programme: anti-complement component C3 proteases - Catalyst Biosciences

Drug Profile

Research programme: anti-complement component C3 proteases - Catalyst Biosciences

Alternative Names: anti-C3 protease - Catalyst Biosciences; CB 2782

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catalyst Biosciences
  • Developer Catalyst Biosciences; Mosaic Biosciences
  • Class Peptide hydrolases
  • Mechanism of Action Complement C3 inhibitors; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry age-related macular degeneration; Retinal disorders

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Retinal disorders
  • Discontinued Delayed graft function; Inflammation

Most Recent Events

  • 31 Oct 2017 Catalyst Biosciences and Mosaic Biosciences enter into collaboration to develop intravitreal anti-complement component C3 proteases for the treatment of Dry-age related macular degeneration and Retinal disorders
  • 24 Oct 2017 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous)
  • 24 Oct 2017 Preclinical trials in Retinal disorders in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top